RevMed’s pancreatic cancer drug breezes through with swift approval - Pharmaceutical Technology

Revolution Medicines’ breakthrough drug for pancreatic cancer was approved more than six months ahead of schedule. Revolution Medicines’ breakthrough drug for pancreatic cancer was approved more than six months ahead of schedule. Revolution Medicines’ Rasonque (daraxonrasib), a potentially significant drug for pancreatic cancer has been approved by the US Food and Drug Administration. Image Credit: [Migma__Agency]/Shutterstock.com A potentially paradigm-shifting treatment for pancreatic cancer by Revolution Medicines’ (RevMed) named Rasonque (daraxonrasib) has been approved by the US Food and Drug Administration. Rasonque was the headline story at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, with strong clinical results…

Source: Pharmaceutical Technology